GlassScriptPhysician profile
Derek Susalla
NPI 1508392796
$241,533.74
in general payments reported to CMS, 2019-2025
14 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $20K · 2023: $32K · 2024: $73K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $85K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Consulting Fee: $28K · Travel and Lodging: $19K · Food and Beverage: $8,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $84,671.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,450.00 |
| Consulting Fee | $28,463.50 |
| Travel and Lodging | $19,182.20 |
| Food and Beverage | $8,597.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $104,754.30 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $93,144.67 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $37,774.86 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $3,665.81 | 2021-2025 | Rexulti |
| Tris Pharma INC | $586.96 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Lundbeck LLC | $522.50 | 2021-2025 | Rexulti |
| Neos Therapeutics, LP | $290.68 | 2023-2024 | Adzenys Xr-Odt |
| Corium, LLC | $245.09 | 2023-2024 | Azstarys |
| Alkermes, INC. | $140.74 | 2024 | Vivitrol, Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $138.18 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $123.50 | 2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $80.39 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $46.64 | 2023-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $19.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Susalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.